Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Early Alopecia May Be Linked to Prostate Cancer

December 12th 2011

New data support a potential link between early-onset androgenic alopecia and the development of prostate cancer.

Prostate Cancer Test Deemed Unnecessary by Government Panel

December 8th 2011

After decades of use, a routine test used for diagnosing prostate cancer has come under fire after a government panel questioned its safety.

Dr. Alter Discusses Provenge MOA and Tolerability

December 2nd 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Dr. Petrylak on Sequencing Prostate Cancer Therapies

December 1st 2011

Dr. Daniel Petrylak from Herbert Irving Comprehensive Cancer Center Discusses Sequencing Prostate Cancer Therapies

Recent Advances Put Focus on Tumor Microenvironment

November 30th 2011

The impact that the tumor microenvironment has on the survival and growth of cancer cells is becoming increasingly well defined on several fronts.

Dr. Sartor Discusses Prostate Cancer Drug Combinations

November 29th 2011

Dr. Oliver Sartor from Tulane Cancer Center Discusses Prostate Cancer Drug Combinations

Dr. Alter Discusses the Provenge Treatment Process

November 17th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process

Dr. Sartor Discusses the Novel Agent Radium-223

November 15th 2011

Dr. Oliver Sartor from Tulane Cancer Center Discusses the Novel Agent Radium-223

Dr. Alter Discusses the Immunotherapy Provenge

November 11th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Denosumab Delays Onset of Metastases in Castration-Resistant Prostate Cancer

October 18th 2011

Inhibiting the RANKL protein, which is involved in bone metabolism, can delay the onset of the bone metastases in men with castration-resistant prostate cancer.

Changing Fate of Bone-Related Therapies for Prostate Cancer

October 18th 2011

Two trials are underway that not only address bone-related issues but might improve survival rates for patients.

Vitamin E Supplements Linked to Increased Risk of Prostate Cancer

October 12th 2011

Vitamin E may increase the risk of developing prostate cancer in men who have taken the supplement for 5 years or longer.

Pharmaceutical Company Profile: Dendreon Corporation

October 4th 2011

Dendreon estimates that only about 25% of eligible prescribing physicians were aware that Medicare had decided to cover Provenge for its on-label use of treating prostate cancer.

Survival Benefit Shown With Investigational Alpha-Emitting Radiopharmaceutical in Men With Hormone Resistant Metastatic Prostate Cancer

September 24th 2011

Investigational drug that emits alpha radiation shows significant improvement in overall survival.

Two Predictors of Prostate Cancer Explored in Healthy Men

September 23rd 2011

Two studies enhance understanding of risk factors for prostate cancer.

Value-Based Coverage Decisions: CMS Scrutinizes Provenge

August 25th 2011

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

ASCO Highlights: Trials in Progress

August 23rd 2011

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Cost/Benefit Ratio of Denosumab Is Questionable When Treating Patients With Metastatic CRPC

July 29th 2011

The use of denosumab to prevent SREs in men with mCRPC has questionable cost-effectiveness as compared with zoledronic acid.

Amgen Seeks to Expand Xgeva's FDA Approval

July 11th 2011

A pivotal phase III study found that men with CRPC experienced prolonged bone metastasisâ€“free survival with Xgeva versus placebo.

Acetaminophen Use May Cut Risk of Prostate Cancer

July 6th 2011

New findings suggest that long-term, regular acetaminophen use may be associated with a lower risk of prostate cancer.